Bio-Rad Laboratories Files 8-K
Ticker: BIO-B · Form: 8-K · Filed: Sep 30, 2025 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
Related Tickers: BIO
TL;DR
BIO files 8-K, check for updates.
AI Summary
Bio-Rad Laboratories, Inc. filed an 8-K on September 30, 2025, reporting events as of September 29, 2025. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates that Bio-Rad Laboratories, Inc. is making disclosures to the SEC, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific material events or financial data, indicating low immediate risk.
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — Registrant
- September 29, 2025 (date) — Earliest event date
- September 30, 2025 (date) — Filing date
- 1000 Alfred Nobel Drive, Hercules, California 94547 (location) — Principal executive offices
FAQ
What specific events are being disclosed under Regulation FD?
The provided excerpt does not specify the exact events being disclosed under Regulation FD.
Are there any financial statements included in this filing?
Yes, the filing indicates that Financial Statements and Exhibits are included, but the excerpt does not contain the statements themselves.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on Regulation FD Disclosure and to file Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 29, 2025.
What is Bio-Rad Laboratories, Inc.'s principal executive office address?
The principal executive office is located at 1000 Alfred Nobel Drive, Hercules, California 94547.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-09-30 06:02:36
Key Financial Figures
- $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Filing Documents
- bio-20250929.htm (8-K) — 33KB
- bio-8k09302025xex991.htm (EX-99.1) — 6KB
- image_0a.jpg (GRAPHIC) — 14KB
- 0000012208-25-000057.txt ( ) — 213KB
- bio-20250929.xsd (EX-101.SCH) — 2KB
- bio-20250929_def.xml (EX-101.DEF) — 15KB
- bio-20250929_lab.xml (EX-101.LAB) — 27KB
- bio-20250929_pre.xml (EX-101.PRE) — 16KB
- bio-20250929_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 29, 2025, Bio-Rad Laboratories, Inc. (the "Company") announced that Alice N. Schwartz, the Company's co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99. A copy of the press release is furnished with this report as Exhibit 99.1. The information contained in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press release dated September 29 , 2025 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: September 30, 2025 By: /s/ Courtney C. Enloe Courtney C. Enloe Executive Vice President, General Counsel & Secretary